In a report released today, Michael Matson from Needham maintained a Hold rating on Merit Medical Systems (MMSI). The company’s shares closed last Monday at $26.27, close to its 52-week low of $19.50.
According to TipRanks.com, Matson is a 5-star analyst with an average return of 7.0% and a 61.6% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Cardiovascular Systems, and Zimmer Biomet Holdings.
Merit Medical Systems has an analyst consensus of Moderate Buy, with a price target consensus of $32.00.
See today’s analyst top recommended stocks >>
Merit Medical Systems’ market cap is currently $1.45B and has a P/E ratio of 79.15. The company has a Price to Book ratio of 1.53.
Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MMSI in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Merit Medical Systems, Inc. engages in the manufacture and market of proprietary disposable medical devices. It operates through Cardiovascular and Endoscopy segments. The Cardiovascular segment consists of peripheral intervention, cardiac intervention, interventional oncology and spine, and cardiovascular and critical care product groups.
